Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens-Reference-Cited by-同舟云学术

Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens

Published:2021-03 Issue:3 Volume:110 Page:1042-1053
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Sawant Nishant,Kaur Kawaljit,Holland David A.,Hickey John M.,Agarwal Sanjeev,Brady Joseph R.,Dalvie Neil C.,Tracey Mary Kate,Velez-Suberbie M. Lourdes,Morris Stephen A.,Jacob Shaleem I.,Bracewell Daniel G.,Mukhopadhyay Tarit K.,Love Kerry R.,Love J. Christopher,Joshi Sangeeta B.,Volkin David B.

Funder

Bill and Melinda Gates Foundation

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference40 articles.

1. The complexity and cost of vaccine manufacturing–an overview;Plotkin;Vaccine,2017

2. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design;Rappuoli;J Exp Med,2016

3. Modern subunit vaccines: development, components, and research opportunities;Moyle;Chem Med Chem,2013

4. Vaccine adjuvants: putting innate immunity to work;Coffman;Immunity,2010

5. Advances in aluminum hydroxide-based adjuvant research and its mechanism;He;Hum Vaccines Immunother,2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between protein conformational stability and its immunogenicity when administering antigens to mice using adjuvants—Analysis employed the CH2 domain in human antibodies;PLOS ONE;2024-07-22

2. Relationship between Protein Conformational Stability and Its Immunogenicity When Administering Antigens to Mice Using Adjuvants;2023-10-31

3. Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines;Vaccine;2023-10

4. Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines;2023-04-04

5. Minimal purification method enables developability assessment of recombinant proteins;Biotechnology and Bioengineering;2023-04-03